Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24)-Pipeline Review, H1 2018

Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24)-Pipeline Review, H1 2018


  • Products Id :- GMDHC1440TDB
  • |
  • Pages: 69
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24)-Pipeline Review, H1 2018

Summary

According to the recently published report 'Mitogen Activated Protein Kinase 14-Pipeline Review, H1 2018'; Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.

Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24)-Mitogen-activated protein kinase 14 also called p38-alpha is an enzyme belongs to p38 MAPK family.

p38-alpha MAPK play an important role in the cascades of cellular responses evoked by extracellular stimuli such as proinflammatory cytokines or physical stress leading to direct activation of transcription factors. p38-alpha MAPK is expressed in many cell types. p38-alpha MAPK is implicated in cell apoptosis, proliferation, differentiation, migration, mRNA stability, and inflammatory response in different cell types through variety of different target molecules.

The report 'Mitogen Activated Protein Kinase 14-Pipeline Review, H1 2018' outlays comprehensive information on the Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) targeted therapeutics development with respective active and dormant or discontinued projects.

Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 7 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Oncology, Immunology, Gastrointestinal, Genito Urinary System And Sex Hormones, Ophthalmology and Undisclosed which include indications Alzheimer's Disease, Pancreatic Cancer, Acute Ischemic Stroke, Age Related Macular Degeneration, Breast Cancer, Chronic Inflammation, Chronic Pain, Dilated Cardiomyopathy, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Focal Segmental Glomerulosclerosis (FSGS), Glioblastoma Multiforme (GBM), Ischemic Stroke, Melanoma, Mild Cognitive Impairment, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Neuropathic Pain, Non-Small Cell Lung Cancer, Peritoneal Cancer, Post-Operative Pain, Rheumatoid Arthritis, Ulcerative Colitis and Unspecified.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24)

The report reviews Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) targeted therapeutics and enlists all their major and minor projects

The report assesses Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24)-Overview

Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24)-Companies Involved in Therapeutics Development

Allinky Biopharma

Array BioPharma Inc

AstraZeneca Plc

Eli Lilly and Co

GlaxoSmithKline Plc

Ionis Pharmaceuticals Inc

Synovo GmbH

TopiVert Ltd

Zocere Inc

Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24)-Drug Profiles

AIK-3a-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Oligonucleotides to Inhibit MAPK14 for Pain-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARRY-797-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

losmapimod-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MW-150-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

neflamapimod-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pamapimod-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Inhibit MAPK14 and MAPK11 for Rheumatoid Arthritis, Multiple Sclerosis and Pancreatic Cancer-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ralimetinib mesylate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptide to Inhibit MAPK14 for Ischemic Stroke-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Mitogen Activated Protein Kinase 14 for Alzheimer's Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit p38alpha MAP Kinase for Chronic Inflammation-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SYD-003-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TOP-1210-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24)-Dormant Products

Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24)-Discontinued Products

Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24)-Product Development Milestones

Featured News & Press Releases

Mar 07, 2018: EIP Pharma Publishes Positive Alzheimer's Disease Clinical Study Data with Neflamapimod

Jul 18, 2017: EIP Pharma announces presentation of new positive clinical data with neflamapimod at Alzheimer's Association International Conference

Dec 08, 2016: EIP Pharma announces positive results with neflamapimod (VX-745) in two Phase 2a clinical trials in patients with Early Alzheimers Disease

Nov 16, 2016: EIP Pharma announces upcoming oral presentations of Phase 2a clinical trial results with neflamapimod (VX-745) at Clinical Trials in Alzheimer's Disease (CTAD) conference Dec 8-10,

Sep 28, 2016: EIP Pharma announces issuance of multiple new patents covering VX-745, a selective p38 MAP kinase alpha inhibitor for Alzheimers disease and ischemic stroke recovery

Aug 30, 2016: Array Presents Data from Cardiovascular Trial with ARRY-797 at the European Society of Cardiology Congress

Aug 20, 2016: Array BioPharma Announces Clinical Data Presentation On ARRY-797 At The 2016 European Society Of Cardiology Congress

Dec 16, 2015: EIP Pharma announces scientific publication of results demonstrating pro-cognitive effects in aged rats of VX-745, a clinical stage selective p38 MAP kinase alpha Inhibitor

Oct 27, 2015: GSK provides update on LATITUDE-TIMI 60 (losmapimod cardiovascular study)

Jul 15, 2015: Zocere's Brain Saving Drug Issued U.S. Patent

Jun 03, 2015: EIP Pharma announces first patient dosing in phase 2 clinical studies of a novel brain-targeted anti-inflammatory drug candidate, VX-745, for the treatment of Alzheimer's disease

Jan 07, 2015: Zocere to Present Brain-Protecting Drug at Biotech Showcase

Oct 14, 2014: Zocere Showcases Brain Saving Drug at Life Sciences Summit in New York City

Oct 01, 2014: Zocere's Stroke Drug to Be Featured at BIO Investor Forum

Sep 23, 2014: Public summary of opinion on orphan designation

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development by Stage of Development, H1

Number of Products under Development by Therapy Areas, H1

Number of Products under Development by Top 10 Indications, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H1

List of Tables

Number of Products under Development by Stage of Development, H1

Number of Products under Development by Therapy Areas, H1

Number of Products under Development by Indications, H1

Number of Products under Development by Indications, H1 2018 (Contd..1), H1

Number of Products under Development by Companies, H1

Products under Development by Companies, H1

Products under Development by Companies, H1 2018 (Contd..1), H1

Number of Products under Investigation by Universities/Institutes, H1

Products under Investigation by Universities/Institutes, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Pipeline by Allinky Biopharma, H1

Pipeline by Array BioPharma Inc, H1

Pipeline by AstraZeneca Plc, H1

Pipeline by Eli Lilly and Co, H1

Pipeline by GlaxoSmithKline Plc, H1

Pipeline by Ionis Pharmaceuticals Inc, H1

Pipeline by Synovo GmbH, H1

Pipeline by TopiVert Ltd, H1

Pipeline by Zocere Inc, H1

Dormant Products, H1

Dormant Products, H1 2018 (Contd..1), H1

Dormant Products, H1 2018 (Contd..2), H1

Dormant Products, H1 2018 (Contd..3), H1

Discontinued Products, H1

Discontinued Products, H1 2018 (Contd..1), H1

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Allinky Biopharma

Array BioPharma Inc

AstraZeneca Plc

Eli Lilly and Co

GlaxoSmithKline Plc

Ionis Pharmaceuticals Inc

Synovo GmbH

TopiVert Ltd

Zocere Inc

select a license
Single User License
USD 3500 INR 245000
Site License
USD 7000 INR 490000
Corporate User License
USD 10500 INR 735000

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com